<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="321">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422110</url>
  </required_header>
  <id_info>
    <org_study_id>N01272</org_study_id>
    <nct_id>NCT00422110</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures</brief_title>
  <official_title>A Phase IIb/III, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Seletracetam as Adjunctive Treatment in Subjects (â‰¥16 to 70 Years Old) With Refractory Partial Onset Seizures.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness and safety of seletracetam when it is used in
      addition to other anti-epileptic medications by patients with partial onset seizures. It
      will also help to determine the best dose to use.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2008</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the efficacy of seletracetam compared to placebo in reducing seizure frequency in subjects with partial onset seizures not fully controlled despite treatment with 1 - 2 concomittant AEDs</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore the dose/clinical response relation; safety and tolerability; effects of treatment on patients' Health-Related Quality of Life (HRQoL)</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Epilepsies, Partial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seletracetam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects from 16 to 70 years old

          -  Confirmed diagnosis of focal epilepsy

          -  Partial seizures uncontrolled while taking 1 or 2 AEDs

          -  At least 8 partial seizures during the 8-week baseline period

        Exclusion Criteria:

          -  Seizures occurring only in clusters

          -  Status epilepticus within 1 year

          -  Progressive CNS disorder

          -  Other serious or uncontrolled diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Bennett, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 25, 2012</lastchanged_date>
  <firstreceived_date>January 11, 2007</firstreceived_date>
  <keyword>Seletracetam</keyword>
  <keyword>Epilepsies</keyword>
  <keyword>Partial</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Focal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
